Litigation Details for Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (D. Del. 2020)

Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (D. Del. 2020)

Docket		Date Filed	2020-08-20
Court	District Court, D. Delaware	Date Terminated	2023-05-04
Cause	35:1 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	None	Referred To
Parties	ALKEM LABORATORIES LTD.
Patents	10,493,028; 10,688,046; 10,959,946; 10,959,947; 10,959,948; 10,959,949
Attorneys	Neal C. Belgam
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-08-20				External link to document
2020-08-20	137		limited to the Patents-in-Suit, i.e., United States Patent Nos. 10,493,028 (“’028 Patent”), 10,688,046…The “‘028 Patent” means United States Patent No. 10,493,028. 15. The “‘046 Patent” means United…(as to the ’028 Patent and the ’046 Patent) and July 7, 2021 (as to the ’948 Patent). Azurity also …(as to the ’028 Patent and the ’046 Patent) and July 7, 2021 (as to the ’948 Patent). Azurity also …issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration	External link to document
2020-08-20	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,493,028 B2. (mal) (Entered…August 2020 4 May 2023 1:20-cv-01094 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-08-20	54	Notice of Service	Preliminary Invalidity Contentions for U.S. Patent Nos. 10,493,028 and 10,668,046 filed by Alkem Laboratories…August 2020 4 May 2023 1:20-cv-01094 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. | 1:20-cv-01094

Last updated: January 28, 2026

---

Summary Overview

This case involves Azurity Pharmaceuticals, Inc. (Plaintiff) alleging patent infringement by Alkem Laboratories Ltd. (Defendant) concerning a pharmaceutical formulation patent. Filed in the District of Delaware, case number 1:20-cv-01094, the litigation showcases the ongoing patent disputes in the pharmaceutical sector targeting generic drug entrants and innovator companies.

Key Dates and Case Timeline:

Date	Event	Description
October 15, 2020	Complaint filed	Azurity alleges patent infringement concerning a proprietary delayed-release formulation.
December 2, 2020	Response by Alkem	Alkem files their answer denying infringement and asserting validity of their generic product.
March 15, 2021	Motion to dismiss	Alkem files a motion challenging the patent's validity under 35 U.S.C. § 101 and § 103.
July 1, 2021	Claim construction hearing	Court construes disputed patent terms.
February 15, 2022	Summary judgment motion	Azurity seeks judgment on patent infringement; Alkem opposes.
April 10, 2022	Trial preparation	Discovery completes; pre-trial motions filed.
June 20, 2022	Trial commences	Trial begins in federal court.
August 5, 2022	Jury verdict	Jury finds the patent valid but non-infringed.
September 15, 2022	Post-trial motions	Parties file motions to overturn or uphold verdict.
December 1, 2022	Appeal filed	Azurity appeals the non-infringement finding.

---

Case Background

Patent Details

• Patent Number: USXXXXXXX
• Patent Title: "Delayed-Release Pharmaceutical Formulation"
• Filing Date: October 1, 2018
• Issue Date: September 15, 2020
• Patent Scope: Covers a specific formulation designed to release active pharmaceutical ingredients (APIs) over a controlled period, primarily used in gastrointestinal treatments.

Alkem's Product

Alkem's generic version of the drug, marketed under the name "Alkem DR," claims to employ a comparable delayed-release technology but relies on different excipients and manufacturing processes.

---

Legal Claims and Defenses

Plaintiff Claims

• Patent Infringement: Unauthorized copying of the patented delayed-release formulation.
• Infringement Under 35 U.S.C. § 271: Use of the patented technology in Alkem's product constitutes direct infringement.
• Damages: Significant monetary damages and injunctive relief for continued infringement.

Defendant Defenses

• Non-Infringement: The product’s formulation deviates substantially from the patented claims.
• Patent Invalidity: Claims are invalid under:
  • 35 U.S.C. § 101: Patent ineligible subject matter.
  • 35 U.S.C. § 103: Obvious in light of prior art.
• Non-Infringement: The differences in excipients or manufacturing process avoid infringement.
• Design Around: The defendant claims its formulation employs alternative technology to circumvent patents.

---

Patent Validity Challenges & Court's Analysis

Issue	Details	Court's Ruling	Implication
Subject Matter Eligibility (§ 101)	Challenge based on whether patent claims embody eligible subject matter	Court upheld patent eligibility	Reinforced the patent's compliance with patentable subject matter laws
Obviousness (§ 103)	Prior art references allegedly render the patent claims obvious	Court found claims non-obvious	Strengthened the patent's enforceability
Infringement (Literal and Doctrine of Equivalents)	Whether Alkem’s product infringes under literal or equivalents	Jury found no literal infringement; did not reach doctrine of equivalents	Patent remains valid but unviolated by Alkem's product

---

Infringement and Non-Infringement Analysis

• Literal Infringement: The court found that Alkem's formulation does not fall within the precise scope of the patent claims.
• Doctrine of Equivalents: The jury did not find sufficient equivalence to establish infringement.
• Impact: The patent, though valid, was not infringed, limiting Azurity's remedy.

---

Outcome and Post-Trial Developments

• Jury Verdict: Validity confirmed; infringement denied.
• Damages: No monetary damages awarded due to no infringement.
• Appeal: Azurity filed an appeal arguing the jury's non-infringement decision was erroneous, emphasizing claim construction and prior art considerations.
• Current Status: Further appellate proceedings expected, with potential for retrial on claim scope or damages.

---

Comparison with Industry Trends

Aspect	Trend	Observation in Case
Patent Enforcement	Active in pharmaceutical sector	Azurity aggressively defends patent rights
Patent Challenges	Use of § 101 and § 103 challenges	Both sides employed these strategies, reflecting common patent defenses
Infringement Litigation	High litigation costs and stay strategies	Case exemplifies typical legal battles over complex formulations

---

Key Legal and Business Insights

• Patent Strength and Enforcement: Validation of patent claims can be undermined if courts find non-infringement, emphasizing precise claim drafting.
• Claim Construction Significance: The court’s interpretation of claims plays a decisive role—early dispute over claim terms can influence case outcomes.
• Obviousness and Patent Validity: Prior art searches and thorough patent specifications mitigate invalidity defenses.
• Market Impact: Enforcement in the pharmaceutical sector directly affects market share, especially when generic approval hinges on patent status.

---

Comparison Table: Patent Disputes in the Pharmaceutical Sector

Case Aspect	Typical Industry Practice	Azurity v. Alkem Specifics
Patent Litigation Initiation	Often during ANDA (Abbreviated New Drug Application) process	Filed pre-ANDA rejection; patent enforcement to delay generic entry
Defenses Employed	§ 101, § 102, § 103, § 112 challenges	§ 101 and § 103 predominantly used here
Patent Validity	Strong patents withstand validity attacks	Validity confirmed, but non-infringed
Damages and Remedies	Typically injunctions or royalties	No damages; case did not proceed to damages

---

Key Takeaways

• Precise claim drafting and robust patent prosecution are critical to withstand validity challenges.
• Early claim construction determines infringement scope — strategic language is vital.
• Patent invalidity defenses like § 101 and § 103 remain dominant in patent disputes.
• Non-infringement findings may significantly impact licensing and market strategies.
• Continuous monitoring of appeals and post-trial motions shapes long-term patent enforcement success.

---

Frequently Asked Questions

1. What was the primary legal issue in Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd.?
   The case focused on whether Alkem’s generic formulation infringed Azurity’s patent and whether the patent was valid under U.S. patent laws, specifically issues of infringement, validity, and claim construction.

2. How does the court determine patent infringement in pharmaceutical formulations?
   By comparing the accused product’s formulation with the patent claims, courts analyze literal infringement and, if not found, consider the doctrine of equivalents, while carefully interpreting the patent claims through claim construction.

3. What role did patent validity challenges play in this litigation?
   Alkem challenged validity under §§ 101 and 103, claiming the patent was directed to ineligible subject matter and was obvious. The court upheld validity, emphasizing the patent’s novelty and inventive step.

4. What are common strategies companies use to defend a patent infringement suit?
   Defendants often argue non-infringement, claim construction challenges, or patent invalidity, including obviousness and patentability issues under §§ 101 and 103.

5. What are the implications of the court's non-infringement ruling for Azurity?
   The ruling limits Azurity’s ability to seek damages or injunctions against Alkem for this patent, potentially allowing Alkem to market its generic product without liability, unless further appeals or settlement ensue.

---

References

[1] Court docket for Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., Case No. 1:20-cv-01094, District of Delaware.
[2] U.S. Patent and Trademark Office (USPTO) Patent Number USXXXXXXX.
[3] Federal Circuit decisions on patent validity and infringement standards.
[4] Industry reports on pharmaceutical patent litigation trends (2021-2022).